Document is current

Article History

Received: 5 August 2025

Accepted: 27 September 2025

First Online: 21 October 2025

Declarations

:

: Ignacio Martin-Loeches reports speaker fees and/or research funding from Mundipharma, Gilead, Pfizer, MSD, and Menarini. Oliver A. Cornely reports grants or contracts from iMi, iHi, DFG, BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from numerous companies, including AbbVie, GSK, IQVIA, Janssen, MedPace, Menarini, and Shionogi; speaker and lecture honoraria from various institutions and industry partners; expert testimony for Cidara; and participation on advisory boards. David W. Denning holds founder shares in F2G Ltd., a University of Manchester spin-out antifungal discovery company; is or has recently been a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Pfizer, Omega, Novacyt, Rostra Pharmaceuticals, MucPharm, Mundipharma, Lifemine, and Cipla; chairs a Data Review Committee for Pulmocide and acts as a Phase 1 Medical Monitor for Biosergen; has been paid for talks on behalf of BioRad, Basilea, and Pfizer; and is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group and the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group, and recently joined the One World Guideline for Aspergillosis. Jesús Guinea has received funds for educational activities and research from Gilead, Pfizer, Mundipharma, FIS, F2G, Shionogi, and Scynexis. Matteo Bassetti declares consulting and research support from Advanz, Cidara, Gilead, Menarini, MSD, Pfizer, Shionogi, and Mundipharma. Johan Maertens reports grants, consultancy, and speaker fees from F2G, Gilead, MSD, Pfizer, Mundipharma, and others; has received expert witness payments from Cidara, Mundipharma, and F2G. Martin Hoenigl reports grants and research funding from Gilead, Astellas, MSD, IMMY, Pulmocide, Shionogi, GSK, Melinta, Mundipharma, Scynexis, F2G, and Pfizer, unrelated to the current work. Souha S. Kanj reports speaker and advisory roles for Pfizer, MSD, Menarini, Hikma, and Astellas. Monica Slavin is a speaker and/or advisory board member for Pfizer, Gilead, Merck Sharp & Dohme (MSD), and F2G; and has received research support from Pfizer, Gilead, MSD, and F2G. Luis Ostrosky-Zeichner has received research funding and/or consulting honoraria from the following companies: Scynexis, Melinta, GSK, Pulmocide, F2G, Basilea, Pfizer, Gilead, T2 Biosystems, Octapharma, Meiji, Knight, and Eurofins Viracor. He is partially funded by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through UTHealth-CCTS Grant Number UL1TR003167 and contract U01CK000692, Centers for Disease Control and Prevention. Patricia Muñoz has served as a speaker and/or consultant for Basilea, Gilead, MSD, Mundipharma, Pfizer, Roche, Pharmamar SAU, and Menarini; received support from Fundación de Ciencias de la Salud, UIMP, Future Day Foundation, and Fundación SEIMC-GESIDA; and research funding from Pharmamar, FIS, CIBERES, Mutua Madrileña, EU funds, and Fundación Pública Andaluza.